AsymBio

AsymBio Team is at 15th World ADC London! Our Senior Director Dr. Shujing Wang, delivered a speech entitled "Overcoming Challenges in ADC Drug Product Development by Leveraging an Integrated Platform ", which dived into actionable insights and pioneering approaches shaping the next generation of therapies. Swing by our booth #36 and let’s connect! #ADC #DS #DP #London #CDMO #manufacuturing #bioconjugates

AsymBio, the subsidiary of Asymchem Laboratories (Stock Code: 002821.SZ/6821.HK), announced the official inauguration of CDMO base in Fengxian, Shanghai. This facility will provide late-stage clinical and commercial manufacturing services for antibodies and bioconjugates. Spanning over 120,000 square meters, the Fengxian Facility is designed to meet growing global demand for innovative biologics. The Phase IA facility now operational features:  - Antibody Drug Substance (DS): 2,000L single-use bioreactors and purification lines.  - Antibody Drug Product (DP): B+A grade fill-finish lines with ORABS and 20 m² lyophilizer, supporting 2R-20R vials. Phase IB, set for completion by late 2025, will add ADC DS and DP workshops. Future phases will integrate QC labs, R&D centers, and operational hubs to enhance AsymBio’s one-stop service ecosystem. The Fengxian Facility complements AsymBio’s existing Jinshan facility, which offers GMP-compliant antibody and ADC production capacities including:  - Antibody DS at 200L/500L/2000L scales.  - ADC DS production at 100L/200L/500L scales. - Fully isolated automated filling lines and lyophilizers (5 m²–10 m²), enabling 6R-20R vial services. The company’s quality system adheres to NMPA, FDA, EMA, and ICH guidelines, with successful EU QP audits and MNC client inspections. Its project management expertise spans clinical strategy to multi-module execution, ensuring agile support for partners worldwide. AsymBio currently supports 21 out of 27 Chinese biopharma companies' licensing-out ADC projects, cementing its role as a critical partner in the bioconjugate supply chain. AsymBio aims to empower global innovators with integrated and reliable CDMO solutions. #AsymBio #Asymchem #NMPA #FDA #EMA #ICH #MNC #biotech #antibody #bioconjugate #

AsymBio is Thrilled to Join the 15th World ADC in London! Mark your calendars for March 3rd–6th, 2025. We will be at Booth #36 to showcase cutting-edge integrated solutions for your bioconjugates! Whether you’re tackling complex PD challenges or scaling up production, our experts are ready to collaborate and innovate with you. Don’t miss this chance to explore the future of ADC technology. Swing by our booth and let’s connect! Special Highlight: On March 4th, join Dr. Shujing Wang, our Senior Director of Drug Product Development, as she takes the stage in the Process & Analytical Development Session. Her presentation, “Challenges and Strategies for ADC Drug Product Development,” will dive into actionable insights and pioneering approaches shaping the next generation of therapies. We’re excited to share knowledge, forge partnerships, and push the boundaries of what’s possible in bioconjugates. See you in London! #ADCs #Bioconjugates #DrugDevelopment #InnovationInHealthcare #WorldADCLondon #PharmaLeadership  #CDMO #DS #DP

Radionuclide Drug Conjugates (RDCs) hold the potential to transform cancer treatment by offering effective, precise treatment and diagnosis with minimal side effects. Regulators have already approved several RDCs around the world, and more are in the pipeline as researchers seek to further improve their efficacy, safety, and personalization AsymBio offers comprehensive and integrated RDC CDMO services for global clients. Connect with us for more information! #bioconjugates #RDC #Radionuclide #CDMO #ADC #cancer

CSPC Pharmaceutical Group’s subsidiary, CSPC Megalith Biopharmaceutical, has entered into an exclusive license agreement with Radiance Biopharma for the development and commercialization of their anti-cancer drug SYS6005 in various international markets. This agreement allows CSPC to receive significant upfront and potential milestone payments, enhancing its position in the global pharmaceutical market and potentially advancing cancer treatment options. #ADC #CSPC #Radiance #global #CDMO #DS #DP

🚀 We are excited to announce that Asymbio will be exhibiting at BIOCHINA 2025! Join us from March 12-15 in Suzhou to explore our latest innovations in [industry/biotech field]. Let’s connect, collaborate, and drive the future of biotech together! 📍 Booth: C3-C083-084 📅 Date: March 12-15, 2025 📍 Location: Suzhou International Expo Center Looking forward to meeting partners, clients, and industry leaders! Let’s innovate together. 🔬💡 🔗 Follow BIOCHINA for more updates: BIOCHINA LinkedIn Homepage #Asymbio #Asymchem #BIOCHINA2025 #Biotech #LifeSciences #Innovation

In the Process & Analytical Development session of 15th World ADC London on 4th March, 2025, Dr. Shujing Wang, Senior Director of Drug Product Development, will give a speech on “Challenges and Strategies for ADC Drug Product Development”. The speech will highlight: · Recent advances in ADC development result in a great deal of molecular diversities in antibody, drug-linker, and payload for the production of ADCs. · Successful drug product development for different ADCs in a CDMO environment requires an understanding how each of DP elements, such as formulation, stability, manufacturing, dosage form, dosage adminstration, can impact each other, and how each of the elements can be influenced by the ADC molecular design.  · Upon reviewing the typical challenges during ADC drug product development and production, from both theoretical and practical perspectives, case studies will be shared in the presentation to demonstrate practical solutions, built upon our platform technologies, can be effectively provided to help meet those challenges often encountered in formulation developability evaluation, light/oxidation protection, lyophilized DP optimization, customized clinical in-use evaluation, etc. #ADC #DP #CDMO #developability #oxidation #CIU #stability #formulation

In the Process & Analytical Development session of 15th World ADC London on 4th March, 2025, Dr. Shujing Wang, Senior Director of Drug Product Development, will give a speech on “Challenges and Strategies for ADC Drug Product Development”. The speech will highlight: · Recent advances in ADC development result in a great deal of molecular diversities in antibody, drug-linker, and payload for the production of ADCs. · Successful drug product development for different ADCs in a CDMO environment requires an understanding how each of DP elements, such as formulation, stability, manufacturing, dosage form, dosage adminstration, can impact each other, and how each of the elements can be influenced by the ADC molecular design.  · Upon reviewing the typical challenges during ADC drug product development and production, from both theoretical and practical perspectives, case studies will be shared in the presentation to demonstrate practical solutions, built upon our platform technologies, can be effectively provided to help meet those challenges often encountered in formulation developability evaluation, light/oxidation protection, lyophilized DP optimization, customized clinical in-use evaluation, etc. #ADC #DP #CDMO #developability #oxidation #CIU #stability #formulation

AsymBio will be attending the 15th World ADC in London during Mar. 3rd-6th, 2025! Come and visit our booth #36 and our experts will be there to discuss with you on how our integrated ADC CDMO solutions can help your projects. #ADC #CDMO #London #DS #DP #Integrated #IND #BLA #Antibody

Need an experienced partner for reliable and efficient ADC CDMO services? AsymBio’s unprecedented ONE total solution for ADCs allow innovators to progress from DNA to IND in 13 months or less! Our integrated end-to-end approach can address multifaceted challenges in payload-linkers, antibodies, conjugation technology etc. to enhance ADC development and manufacturing. Connect with us to get more information! #ADC #IND #antibody #payload #linker #conjugation #FDA #NMPA #PMDA #EMA